4th Quarter - Termination
AVANIR PHARMACEUTICALS for AVANIR PHARMACEUTICALS
Client
Income
—
Expenses
$40,000
Expense method
A: Lobbying Disclosure Act definitions
Terminated
Nov 15, 2022
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act. H.R. 19, S. 2164, Lower Costs, More Cures Act of 2021. H.R. 5376, Build Back Better Act, specifically issues dealing with Medicare.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATHERINE DRATZ FERGUSON | — |
Health Issues HCR
H.R.7667 - Food and Drug Amendments of 2022, specifically provisions regarding the Prescription Drug User Fee Act (PDUFA). H.R.5376 - Inflation Reduction Act of 2022, specifically provisions relating to prescription drug pricing. Issues related to mental health.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATHERINE DRATZ FERGUSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.